SCOLR Pharma (DDD) Announces Positive Results from Its Second 24 Hour CDT-Ondansetron Trial; Discontinues Development of Extended Release Phenylephrine
Tweet Send to a Friend
SCOLR Pharma, Inc. (AMEX: DDD) announced positive preliminary results from pilot bioavailability testing of its refined 24-hour CDT-based ondansetron tablets ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
